Scholarlink

Background <p>The management of follow-up in proliferative verrucous leukoplakia (PVL) cases remains highly challenging due to the absence of established etiological factors and limited understanding of disease progression. The aim of this study was to identify optimal biomarkers of PVL behavior to facilitate decision-making in complex therapeutic management.</p> Methods <p>Salivary levels of matrix metalloproteinases (MMPs) were evaluated in 54 confirmed PVL cases. All patients underwent follow-up at Oral Medicine Department, Dentistry Clinic at University Hospital Pilsen. Unstimulated saliva samples were collected and analyzed for MMP-1, -2, -3, -7, and − 9 concentrations. Criteria for PVL stability and progression were defined. Disease progression in individual cases was retrospectively correlated with salivary MMP levels to identify optimal prognostic markers.</p> Results <p>Assessment of PVL progression and stability was performed 6 months after salivary MMP sampling. Progression was observed in 63% of patients (34/54). Significant associations between elevated salivary MMP levels and PVL progression were confirmed for four of the five MMPs tested. MMP-1, -3, -7, and − 9 emerged as promising markers. A combination of MMP-3 and MMP-7 demonstrated the best prognostic performance, with a sensitivity of approximately 79.5% and a specificity of 89%.</p> Conclusions <p>This is the first study to evaluate salivary MMPs for PVL monitoring. Our findings confirm an association between elevated salivary MMP levels and an increased risk of PVL progression. This non-invasive approach may improve clinical management and follow-up of patients with PVL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The progression of proliferative verrucous leukoplakia can be detected through elevated levels of salivary matrix metalloproteinases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Jan Liska,
  • Nikoleta Molnarova,
  • Jan Netolicky,
  • Petra Hauerova,
  • Marie Karlikova,
  • Ondrej Topolcan,
  • Ladislav Pecen,
  • Martina Pestova,
  • Veronika Liskova

摘要

Background

The management of follow-up in proliferative verrucous leukoplakia (PVL) cases remains highly challenging due to the absence of established etiological factors and limited understanding of disease progression. The aim of this study was to identify optimal biomarkers of PVL behavior to facilitate decision-making in complex therapeutic management.

Methods

Salivary levels of matrix metalloproteinases (MMPs) were evaluated in 54 confirmed PVL cases. All patients underwent follow-up at Oral Medicine Department, Dentistry Clinic at University Hospital Pilsen. Unstimulated saliva samples were collected and analyzed for MMP-1, -2, -3, -7, and − 9 concentrations. Criteria for PVL stability and progression were defined. Disease progression in individual cases was retrospectively correlated with salivary MMP levels to identify optimal prognostic markers.

Results

Assessment of PVL progression and stability was performed 6 months after salivary MMP sampling. Progression was observed in 63% of patients (34/54). Significant associations between elevated salivary MMP levels and PVL progression were confirmed for four of the five MMPs tested. MMP-1, -3, -7, and − 9 emerged as promising markers. A combination of MMP-3 and MMP-7 demonstrated the best prognostic performance, with a sensitivity of approximately 79.5% and a specificity of 89%.

Conclusions

This is the first study to evaluate salivary MMPs for PVL monitoring. Our findings confirm an association between elevated salivary MMP levels and an increased risk of PVL progression. This non-invasive approach may improve clinical management and follow-up of patients with PVL.